首页> 外国专利> METHOD FOR PREDICTING THE DURATION OF THE DIARRHEA AND THE SELECTION OF TACTICS OF TREATMENT

METHOD FOR PREDICTING THE DURATION OF THE DIARRHEA AND THE SELECTION OF TACTICS OF TREATMENT

机译:预测腹泻持续时间和治疗策略选择的方法

摘要

FIELD: medicine.;SUBSTANCE: invention relates to the field of medicine, namely to infectious diseases, and can be used to select treatment tactics in patients with acute intestinal infections (AII). Method includes the administration of Galavit in addition to standard etiotropic and pathogenetic therapy, with the content of intestinal interleukin-6 (IL-6) in the coprofilter prior to initiation of therapy. At the level of intestinal IL-6, 1–18 pg/ml predict short-term diarrhea: for 1–3 days, with no therapy Galavit. At the level of IL-6, 19–25 pg/mg predict prolonged diarrhea in patients: from 4 to 10 days, while prescribing Galavit sublingually in a dose of 2 tablets once and then 1 tablet 4 times a day for 4–5 days.;EFFECT: use of the invention makes it possible to improve the accuracy of the prognosis in the early stages of the disease, personify Galavit's appointment to patients with acute intestinal infections and predicted protracted course of the disease, reduce the duration of diarrhea and the duration of general symptoms of the disease.;1 cl, 2 tbl, 4 ex
机译:发明领域本发明涉及医学领域,即传染病,可用于选择急性肠道感染(AII)患者的治疗策略。该方法包括在标准的正性和致病性疗法之外施用Galavit,并在开始治疗前将coprofilter中肠道白细胞介素6(IL-6)的含量进行管理。在肠道IL-6的水平上,预测的短期腹泻为1-18 pg / ml:持续1-3天,无需治疗Galavit。在IL-6的水平上,19-25 pg / mg可以预测患者的长时间腹泻:从4天到10天,而舌下以2片的剂量加拉韦处方一次,然后每天4次1片,持续4-5天内效果:本发明的使用使得可以提高疾病早期阶段的预后准确性,使加拉维特(Galavit)被任命为急性肠道感染患者并预测疾病的长期病程,减少腹泻的持续时间和减少疾病一般症状的持续时间。; 1 cl,2 tbl,4 ex

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号